Lantern Pharma, Inc. (LTRN)
| Market Cap | 176.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.91M |
| Shares Out | 11.18M |
| EPS (ttm) | -1.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $15.46 |
| Previous Close | $15.74 |
| Change ($) | -0.28 |
| Change (%) | -1.78% |
| Day's Open | 15.74 |
| Day's Range | 14.90 - 15.92 |
| Day's Volume | 126,351 |
| 52-Week Range | 10.40 - 24.84 |
DALLAS, April 6, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform o...
DALLAS, April 1, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform o...
DALLAS, March 23, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform o...
DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform o...
DALLAS, March 12, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform ...
Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights
DALLAS, March 10, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform ...
The following article is sponsored by Lantern Pharma. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended f...
DALLAS, Jan. 20, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug dev...
DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug dev...
DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to trans...
About LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages ... [Read more...]
| Industry Biotechnology | IPO Date Jun 11, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol LTRN |
Analyst Forecasts
According to 2 analysts, the average rating for Lantern Pharma stock is "Buy." The 12-month stock price forecast is 28.00, which is an increase of 81.11% from the latest price.